Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Open Access
- 14 October 2011
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (20), 6406-6416
- https://doi.org/10.1158/1078-0432.ccr-11-0483
Abstract
When delivered at a sufficient dose and dose rate to a neoplastic mass, radiation can kill tumor cells. Because cancer frequently presents as a disseminated disease, it is imperative to deliver cytotoxic radiation not only to the primary tumor but also to distant metastases, while reducing exposure of healthy organs as much as possible. Monoclonal antibodies and their fragments, labeled with therapeutic radionuclides, have been used for many years in the development of anticancer strategies, with the aim of concentrating radioactivity at the tumor site and sparing normal tissues. This review surveys important milestones in the development and clinical implementation of radioimmunotherapy and critically examines new trends for the antibody-mediated targeted delivery of radionuclides to sites of cancer. Clin Cancer Res; 17(20); 6406–16. ©2011 AACR.Keywords
This publication has 55 references indexed in Scilit:
- Cancer RadioimmunotherapyImmunotherapy, 2011
- A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vesselsBritish Journal of Cancer, 2011
- Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal CarcinomatosisJournal of Nuclear Medicine, 2009
- Affinity and Avidity in Antibody-Based Tumor TargetingCancer Biotherapy & Radiopharmaceuticals, 2009
- 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritisArthritis Research & Therapy, 2009
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostNeuro-Oncology, 2008
- Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6Journal of Nuclear Medicine, 2007
- Pre-Targeted Locoregional Radioimmunotherapy with 90Y-biotin in Glioma Patients: Phase I Study and Preliminary Therapeutic ResultsCancer Biotherapy & Radiopharmaceuticals, 2001